poisar

Stocks · News reference

QuidelOrtho Lowers FY2026 Adj EPS Guidance from $1.80-$2.00 to $0.65-$0.90 vs $1.84 Est; Lowers FY2026 Sales Guidance from $2.700B-$2.750B to $2.520B-$2.600B vs $2.705B Est

Benzinga Newsdesk

QuidelOrtho (NASDAQ:QDEL) lowers FY2026 Adj EPS guidance from $1.80-$2.00 to $0.65-$0.90 vs $1.84 analyst estimate. Lowers FY2026 sales outlook from $2.700 billion-$2.750 billion to $2.520 billion-$2.600 billion vs

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

QDEL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Lateral Flow Assay Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2026-2035

    The global lateral flow assay market is projected to grow from USD 10.84 billion in 2025 to USD 17.66 billion by 2035, with a 5.0% CAGR. Growth is driven by increased adoption of point-of-care testing, technological innovations including CRISPR-based assays, and the shift toward decentralized diagnostic models. Major players include Abbott, Roche, Siemens Healthineers, and Thermo Fisher Scientific, with infectious disease testing accounting for 72.2% of market share.

    ABTRHHBYTMODHRQDEL